ERYTECH announces clinical trial authorizations in Finland and Spain for its European Phase IIb study in AML Post author:admERY Post published:January 15, 2014 Post category:Newsroom ERYTECH announces it received authorizations for its Phase IIb GRASPA-ML clinical trial in Acute Myeloid Leukemia (AML) in Finland and Spain. You Might Also Like ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2020 November 5, 2020 Webinar on Eryaspase in Pancreatic Cancer September 2, 2021 ERYTECH Secures €10 Million in Non-Dilutive Financing, Guaranteed by the French Government November 2, 2020
ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2020 November 5, 2020
ERYTECH Secures €10 Million in Non-Dilutive Financing, Guaranteed by the French Government November 2, 2020